Stuart Poulton is VP at Karyopharm Therapeutics Inc. (KPTI). They have made 13 open-market trades across 1 company since 2023, most recently 2026-07-28.
CIK 0001942597
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KPTI | 94,632 | $37K |
Shares reported on the most recent Form 4, priced at the 2026-07-30 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KPTI | SELL | 2026-07-28 | 2026-07-30 | $7.10 | $1K | -5.0% | -6.1% | — |
| KPTI | SELL | 2026-05-14 | 2026-05-15 | $9.50 | $4K | +17.1% | +23.6% | -74.5% |
| KPTI | SELL | 2026-03-02 | 2026-03-03 | $9.41 | $48K | -13.9% | -35.4% | +7.7% |
| KPTI | SELL | 2026-02-17 | 2026-02-19 | $8.63 | $3K | -5.9% | -31.3% | -17.8% |
| KPTI | SELL | 2025-09-15 | 2025-09-16 | $6.43 | $3K | +5.3% | -3.1% | +7.9% |
| KPTI | SELL | 2025-07-29 | 2025-07-30 | $4.37 | $835 | -4.8% | +79.5% | +59.8% |
| KPTI | SELL | 2025-03-04 | 2025-03-06 | $6.29 | $22K | -6.6% | -35.3% | -30.4% |
| KPTI | SELL | 2025-02-18 | 2025-02-19 | $0.63 | $4K | -21.0% | -30.0% | -43.8% |
| KPTI | SELL | 2024-07-30 | 2024-07-31 | $1.06 | $3K | -16.9% | -22.5% | -13.6% |
| KPTI | SELL | 2024-02-29 | 2024-03-04 | $1.18 | $26K | +1.5% | -2.7% | -25.2% |
| KPTI | SELL | 2024-02-15 | 2024-02-20 | $1.33 | $8K | -0.4% | +19.3% | -4.2% |
| KPTI | SELL | 2023-07-28 | 2023-08-01 | $1.70 | $5K | -9.6% | -31.9% | -56.4% |
| KPTI | SELL | 2023-02-15 | 2023-02-17 | $3.19 | $19K | -12.0% | +0.9% | -31.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.